Expansion of Genetic Testing in the Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University from 2000 to 2013

Kaori Adachi*†
*Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan and †Division of Child Neurology, Department of Brain and Neuroscience, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan

ABSTRACT
Background At the Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, we have been making an effort to establish a genetic testing facility that can provide the same screening procedures conducted worldwide.

Methods Direct sequencing of PCR products is the main method to detect point mutations, small deletions and insertions. Multiplex ligation-dependent probe amplification (MLPA) was used to detect large deletions or insertions. Expansion of the repeat was analyzed for triplet repeat diseases. Original primers were constructed for 41 diseases when the reported primers failed to amplify the gene. Prediction of functional effect of human nsSNPs (PolyPhen) was used for evaluation of novel mutations.

Results From January 2000 to September 2013, a total of 1,006 DNA samples were subjected to genetic testing in the Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University. The hospitals that requested genetic testing were located in 43 prefectures in Japan and in 11 foreign countries. The genetic testing covered 62 diseases, and mutations were detected in 287 out of 1,006 with an average mutation detection rate of 28.5%. There were 77 samples for prenatal diagnosis. The number of samples has rapidly increased since 2010.

Conclusion In 2013, the next-generation sequencers were introduced in our facility and are expected to provide more comprehensive genetic testing in the near future. Nowadays, genetic testing is a popular and powerful tool for diagnosis of many genetic diseases. Our genetic testing should be further expanded in the future.

Key words genetic testing; prenatal diagnosis; germ-line mutation

In Japan, however, genetic testing has not yet become a common practice in the medical field, since public insurance covers only screenings for mutations in 36 genes. Mutation hunting on several genes is conducted on a research basis, which as expected depends on the research project and is not ensured to be provided in the future.

In the Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, we have established a genetic testing facility that can provide the same screening procedures conducted worldwide. This system started as a service for screening mutations responsible for several types of inherited disorders of children, and now has expanded to cover more than 60 inherited disorders. Human DNA samples have been provided not only from Tottori University Hospital but also from other medical facilities all over Japan and foreign countries. Here the development of the system from January 2000 to September 2013 is reported.

SUBJECTS AND METHODS

Subjects
From January 2000 to September 2013, a total of 1,006 DNA samples were subjected to genetic testing in our facility. They were from 13 departments at Tottori University Hospital, 123 hospitals in Japan and 11 in foreign countries (Table 1). Most of the DNA was extracted from peripheral blood. Exceptions include 24 from cultured fibroblasts and 3 from tissue. For prenatal diagnosis, 40 DNA samples were from chorionic villi, 36 from cultured amnionic cells and 1 from umbilical blood. The DNA was subjected to genetic testing for 62 inherited diseases (Table 2).

The samples were collected according to “Guideline for Genetic Testing” (August 2005) approved by the Association of Genetic Medicine (10 societies and

Corresponding author: Kaori Adachi
adachika@med.tottori-u.ac.jp
Received 2013 December 5
Accepted 2013 December 19
Abbreviations: DHPLC, denaturing high performance liquid chromatography; MLPA, multiplex ligation-dependent probe amplification; PolyPhen, prediction of functional effect of human nsSNPs; SSCP, single strand conformation polymorphism
Table 1. The number of medical facilities that requested for genetic testing in our laboratory

| Area       | Number | Prefecture or Country                                      |
|------------|--------|------------------------------------------------------------|
| Hokkaido   | 5      | Aomori 1, Iwate 1, Miyagi 3, Akita 1, Yamagata 2, Fukushima 2 |
| Tohoku     | 10     | Ibaraki 1, Tochigi 3, Gunma 2, Saitama 4, Chiba 2, Tokyo 11, Kanagawa 4 |
| Kanto      | 27     | Niigata 2, Ishikawa 2, Fukui 1, Yamanashi 1, Nagano 1, Gifu 1, Shizuoka 4, Aichi 8 |
| Chubu      | 20     | Mie 3, Shiga 3, Kyoto 2, Osaka 8, Hyogo 3, Nara 1           |
| Kinki      | 20     | Tottori 4, Shimane 1, Okayama 5, Hiroshima 6, Yamaguchi 3  |
| Chugoku    | 19     | Tokushima 1, Kagawa 2                                    |
| Shikoku    | 3      | Fukuoka 5, Saga 1, Nagasaki 2, Kumamoto 1, Oita 4, Miyazaki 1, Kagoshima 3, Okinawa 2 |
| Kyusyu     | 19     | United Kingdom 1, Macedonia 1, United Arab Emirates 1, United States 1, India 1, Singapore 1, Turkey 1, Thailand 1, China 1, Belgium 1, Russia 1 |
| Total      | 123    |                                                            |

*Tottori University Hospital excluded.

Methods

Direct Sequencing of the PCR product is the main method to detect point mutations, small deletions and insertions. In the past, single strand conformation polymorphism (SSCP) and denaturing high performance liquid chromatography (DHPLC) were used in mutation screenings for porphyria, holoprosencephaly and Joubert Syndrome. Mutations in the aberrant PCR product detected by SSCP or DHPLC were confirmed by direct sequencing. SSCP and DHPLC were used from January 2000 to October 2001, and from July 2004 to April 2010, respectively.

The length of the triplet repeat was determined in the diagnosis of myotonic dystrophy, fragile X syndrome and dentatorubral-pallidoluysian atrophy. Multiplex ligation-dependent probe amplification (MLPA) was used for diagnosis of Fabry disease, Rett syndrome, Pelizaeus-Merzbacher disease, Duchenne muscular dystrophy, von Hippel-Lindau disease and spinal muscular atrophy, because these diseases are often caused by large deletions and insertions. Real-time PCR was specially used to detect deletions or insertions in the genes that cause Pelizaeus-Merzbacher disease, Gaucher disease, Menkes disease and metachromatic leukodystrophy.

Disease and gene information

Information on diseases and causative genes was obtained from Online Mendelian Inheritance in Man and Gene database provided by the National Center for Biotechnology Information.

PCR

Before 2009, the primers were designed according to published data with variable rates of successful amplification. From 2010, almost all primers were designed originally in our laboratory using Primer3 software utilizing the gene information from Entrez Gene and RefSeq, resulting in successful amplification in almost all cases. The coding sequence with 70 bp of the flanking area of each exon was amplified by PCR. The annealing temperature was set relatively high (around 63 °C) (Table 2). The sequences of the primers are available on request.

AmpliTaq Gold (Life Technologies, Carlsbad, CA) was routinely used except for the amplification of GC rich sequences (more than 70%). For GC rich sequences, TaKaRa LA Taq (Takara Bio, Otsu, Japan) was used. The reaction mixture contained in a 10 µL reaction volume 10 to 100 ng of template DNA, 2.5 U AmpliTaq Gold, 250 µM or 400 µM dNTP, 1 µM of each primer (forward and reverse) and was run at the following conditions: initial denaturation at 95 °C for 5 min, followed by 30 cycles with denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min, extension at 72 °C for 1 min and final extension at 72 °C for 5 min. For GC-rich or relatively long sequences, 0.5 U TaKaRa LA Taq was used instead of AmpliTaq Gold. The reaction contained 400 µM dNTP and was run as follows: initial denaturation at 94 °C for 1 min, followed by 30 cycles with denaturation at 94 °C for 30 s, annealing at 60 °C for 30 s, extension at 72 °C for 2 min and final extension at 72 °C for 5 min.

For diagnosis of incontinentia pigmenti and Fukuyama-type congenital muscular dystrophy, long insertion or deletion was detected according to the methods described by Bardaro et al. and Kato et al., respectively.

Direct sequencing

PCR products were run on 1.5% of agarose gel electro-
### Table 2. List of inherited diseases surveyed for genetic mutations in our facility

| Disease                                              | Gene symbol | Number of genetic cases |
|------------------------------------------------------|-------------|-------------------------|
| Myotonic dystrophy                                   | DMPK        | 250* 115‡               |
| Fragile X syndrome                                   | FMR1        | 173 19‡                 |
| Niemann-Pick disease type C                          | NPC1†       | 73* 24‡                 |
| GM1 gangliosidosis                                   | GLB1        | 56* 20‡                 |
| Joubert syndrome                                    | NPHP1†, CEP290†, AH1†, TMEM67, RPGRIP1L | 42* 9‡ |
| Gaucher disease                                      | GBA         | 40* 9‡                  |
| Tay-Sachs disease                                    | HEXA        | 38* 12‡                 |
| Porphyria                                            | HMB3†, PPOX†, CPOX† | 38 3‡ |
| Pompe disease                                        | GAA         | 32 8‡                   |
| Cowden syndrome                                      | PTEN        | 30 6‡                   |
| Fabry disease                                        | GLA         | 28 5‡                   |
| Menkes disease                                       | ATP7A†      | 23* 3‡                  |
| Metachromatic leukodystrophy                         | ARSA†       | 19* 4‡                  |
| Rett syndrome/MECP2-related disorders                | MECP2       | 13 4‡                   |
| X-linked hydrocephalus                               | LICAM       | 13* 3‡                  |
| Pelizaeus-Merzbacher disease                         | PLP1        | 11* 3‡                  |
| Fukuyama-type congenital muscular dystrophy         | FKTN        | 10* 4‡                  |
| Nephrogenic diabetes insipidus (NDI)                 | AVPR2       | 10 3‡                   |
| Myotubular myopathy                                 | MTM1†       | 9 1‡                    |
| Galactosialidosis                                    | CTSA        | 8 4‡                    |
| Duchenne muscular dystrophy                          | DMD         | 7* 3‡                   |
| Von Hippel-Lindau disease                            | VHL†        | 5 3‡                    |
| Spinal muscular atrophy                              | SMN1        | 5* 0‡                   |
| Dentatorubral-pallidolouyan atrophy (DRPLA)          | ATN1        | 4 2‡                    |
| Tuberous sclerosis                                   | TSC1, TSC2† | 4 2‡                    |
| Limb-girdle muscular dystrophy type 2B (LGMD2B)      | DYSF        | 4 1‡                    |
| Pendred syndrome                                     | SLC26A4†    | 3 3‡                    |
| Enlarged parietal foramina                           | ALX4†, MSX2† | 3 2‡              |
| Sialidosis                                           | NEU1        | 3 2‡                    |
| Congenital muscular dystrophy-dystroglycanopathy     | FKRIP†      | 3 0‡                    |
| Methylnalonic acidemia                               | MMAA†, MMAB†, MMADHC†, MUT† | 3 0‡ |
| Niemann-Pick disease type C2                         | NPC2†       | 3 0‡                    |
| Benign hereditary chorea                             | NKX2-1      | 2 2‡                    |
| Li-Fraumeni syndrome                                 | TP53        | 2 2‡                    |
| Mucopolysaccharidosis type IVB (Morquio)              | GLB1        | 2 2‡                    |
| Dyschromatosis symmetrical hereditaria               | ADAR†       | 2 1‡                    |
| Incontinentia pigmentii                              | IKBKG       | 2 1‡                    |
| Melanoma                                             | CDKN2A†     | 2 1‡                    |
| Calcium-sensing receptor                             | CASR        | 2 0‡                    |
| Dopamine transporter                                 | SLC6A3      | 2 0‡                    |
| Familial dysautonomia                                | IKBBAP      | 2 0‡                    |
| Holoprosencephaly                                    | SHH, ZIC2†  | 2 0‡                    |
| Lesch-Nyhan syndrome                                 | HPRT1       | 2* 0‡                   |
| Mitochondrial diseases                               | –           | 2 0‡                    |
| Papillon-Lefevre disease                             | CTSC†       | 2 0‡                    |
| Werner syndrome                                      | WRN†        | 1 1‡                    |
| Cereoid lipofuscinosis, neuronal, 1                  | PPT1†       | 1 0‡                    |
| Feingold syndrome                                    | MYCN†       | 1 0‡                    |
| Gardner syndrome                                     | AXIN1†      | 1 0‡                    |
| GM2-gangliosidosis, AB variant                       | GM2A†       | 1 0‡                    |
| Greig cephalopoladactusy syndrome                    | GLI3†       | 1 0‡                    |
| Growth hormone receptor                              | GHR         | 1 0‡                    |
| Klippel-Feil syndrome                                | GDF6†       | 1 0‡                    |
| Leber hereditary optic neuropathy                    | –           | 1 0‡                    |
| Limb-girdle muscular dystrophy type 1C (LGMD1C)      | CAV3        | 1 0‡                    |
| Nevoid basal cell carcinoma syndrome                 | PTCH1†      | 1 0‡                    |
| Niemann-Pick disease type B                          | SMPD1†      | 1 0‡                    |
| Ornithine carbamoyltransferase deficiency disease    | OTC†        | 1 0‡                    |
| Pseudohypoparathyroidism                             | GNAS†       | 1 0‡                    |
| Static acid storage disease                          | SLC21A†     | 1 0‡                    |
| Townes-Brocks syndrome                               | SALL1       | 1 0‡                    |
| Zellweger syndrome                                   | PEX26†      | 1 0‡                    |

Total: 1006 287‡

*The number includes the cases of prenatal diagnosis
†The PCR primers were originally designed in our laboratory
‡The number indicates the cases of mutation.
phoresis and were purified by Ultrafree-DA centrifugal filter unit (Millipore, Billerica, MA). The sequence was determined by using BigDye Terminator v3.1 Cycle Sequencing Kit and capillary sequencer 3130xL Genetic Analyzer (Life Technologies).

SSCP
As described previously, PCR products were separated on 12% polyacrylamide gel at room temperature or 4 °C, and were visualized by silver staining.5

DHPLC
A WAVE-MD Mutation Detection System (Transgenomic, Omaha, NE) based on the DHPLC method was used to detect heteroduplex states according to the manufacturer’s instructions.

Fragment analysis for triplet repeat diseases
PCR in a total volume of 10 µL contained 100 ng of DNA, 2.5 U AmpliTaq Gold DNA Polymerase, 250 µM dNTP, 10% DMSO, 1 µM each primer (forward and reverse), 0.1 µM of the fluorescent labeled probe (FAM, HEX or NED) and was run as follows: initial denaturation at 94 °C for 5 min, followed by 30 cycles with denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, extension at 72 °C for 1 min, and final extension at 72 °C for 5 min. The PCR products were mixed with GeneScan 500 ROX Size Standard (Life Technologies). After incubation at 95 °C for 5 min, the samples were immediately cooled and electrophoresed by 3130xL Genetic Analyzer. Before 2005, ALFred DNA Sequencer (Amersham Pharmacia Biotech, Piscataway, NJ) was used.

MLPA
An MLPA kit (MRC-Holland, Amsterdam, the Netherlands) was used according to the manufacturer’s instructions. In brief, 80 µg of DNA in 6% of glycerol was incubated at 98 °C for 15 min for initial denaturation. The final reaction mixture was electrophoresed by a 3130xL Genetic Analyzer using a 50 cm-long capillary POP-7.

Real-time PCR
When there was any inconsistency in the results of mutations in family members, real-time PCR was used to confirm the presence of deletions or duplications around the mutations.

Data analysis
Sequence data was analyzed by Sequence Scanner (Life Technologies) and Genetyx Software (Genetyx, Shibuya, Japan). Variant Reporter Software (Life Technologies) was used for detection of mutations from 2011. The mutations were confirmed using the human genome mutation database (BIOBASE, Halchtersche, Germany) and SNP database. Prediction of functional effect of human nsSNPs (PolyPhen) was used for evaluation of novel mutations.6

Fragment analysis data was analyzed by Peak Scanner Software v1.0 (Life Technologies) for the repeat size. MLPA data was analyzed by Coffalyzer Software (MRC-Holland).

The personale and running processes of the facility
After October 2010, the working force to run the facility consists of 1 senior medical genetist, 1 assistant profes-

**Table 3. The number of cases subjected to genetic testing from January 2000 to September 2013**

| Year   | Total | Tottori University Hospital | Other hospitals | Number of diseases |
|--------|-------|-----------------------------|-----------------|-------------------|
| 2000   | 6     | 6                           | 0               | 2                 |
| 2001   | 6     | 6                           | 0               | 4                 |
| 2002   | 2     | 2                           | 0               | 1                 |
| 2003   | 7     | 7                           | 0               | 3                 |
| 2004   | 18    | 18                          | 0               | 7                 |
| 2005   | 21    | 21                          | 0               | 8                 |
| 2006   | 44    | 25                          | 19              | 13                |
| 2007   | 43    | 9                           | 34              | 5                 |
| 2008   | 87    | 18                          | 69              | 17                |
| 2009   | 74    | 18                          | 56              | 20                |
| 2010   | 128   | 55                          | 73              | 24                |
| 2011   | 219   | 78                          | 141             | 29                |
| 2012   | 198   | 70                          | 128             | 26                |
| 2013*  | 153   | 54                          | 99              | 27                |
| Total  | 1006  | 387                         | 619             |                   |

* January to September 2013.
Expansion of genetic testing

Fig. 2. A flow chart of the genetic diagnosis using direct sequencing of PCR products. When the system has not been established, it is necessary to obtain the genetic information and design new PCR primers. In this case, it takes at least 3 weeks to detect mutations. When the system has already been established, it takes 2 weeks.

Flow chart of genetic testing
After 2010, it started to take at least 2 weeks for each genetic test to be completed. An additional one and a half weeks is required if it is necessary to settle new screening procedures (Fig. 2). PolyPhen software was used to predict whether any mutation detected was disease-causing or not.

DISCUSSION
We have received a number of requests for genetic testing from all over Japan. Institutes that provide genetic testing are rare, and our institute provides a unique function for the Japanese scientific and medical fields. Actually, genetic testing has contributed to several scientific reports.\textsuperscript{7–18} The number of cases of myotonic dystrophy was particularly high partly because the genetic testing was approved by Ministry of Health, Labour and Welfare of Japan as “highly advanced medical treatment”. It may also be because our facility is the only one approved for conducting prenatal diagnosis of this disease in Japan.\textsuperscript{19} The numbers of cases of fragile X syndrome, Niemann-Pick disease type C, GM1-gangliosidosis and other lysosomal storage diseases are also high because these diseases were the subjects of active research at Tottori University.\textsuperscript{20–22}

Direct sequencing by a capillary sequencer is the main method of genetic testing and the size of the repeat was analyzed for triplet repeat diseases. MLPA was used for deletions or insertions of exons. For Joubert syndrome, 19 or more disease-causing genes were reported. Direct sequencing of every exon of all genes is impractical. In such cases, SSCP or DHPLC was used.
for initial screening. These methods are prone to give false-negative results and it will be better to use next-generation sequencers, which were introduced to Tottori University in 2013. The efficiency of genetic testing has improved and new lines of genetic testing have been enabled since 2010 by the improvement of running processes. Genetic testing is now a popular and powerful tool for diagnosis of many inherited diseases. We should promote it further in the future.

Acknowledgments: I would like to thank: Professor Eijli Nanba and all technical staff of the Division of Functional Genomics, Research Center for Bioscience and Technology for building our system of genetic testing and helpful discussion; Dr. Kousaku Ohno, Emeritus Professor of Tottori University and the staff of the Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine for collection of the samples and helpful discussion; and Professors Tatsu Watanabe, Ichiro Hisatome and Haruki Ninomiya for helpful discussion. I would also like to acknowledge all the doctors at our hospital and other hospitals who provided samples. Finally, thanks to the Center for Promoting Next-Generation Highly Advanced Medicine at Tottori University Hospital, which supported the acceptance of samples and sending reports.

This work was supported by a JPS Grant-in-Aid for Scientific Research (B) 21659257, 22392020 and 25293230, Health Labour Sciences Research Grant (Research on Measures for Intractable Diseases) H21-Intractable-public-022, H22-Intractable-public-002, H22-Intractable-public-014 and H22-Intractable-public-126.

The author declares no conflict of interest.

REFERENCES

1. Jacob HJ. Next-generation sequencing for clinical diagnostics. N Engl J Med. 2013;369:1557-8. PMID: 24088040.
2. Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet. 2012;13:565-75. PMID: 22805709.
3. Bardaro T, Falco G, Sparago A, Mercadante V, Gean Molins E, Tarantino E, et al. Two cases of misinterpretation of molecular results in incontinentia pigmenti, and a PCR-based method to discriminate NEMO/IKKgamma dene deletion. Hum Mutat. 2003;21:8-11. PMID: 12497627.
4. Kato R, Kawamura J, Sugawara H, Niikawa N, Matsumoto N. A rapid diagnostic method for a retrotransposonal insertional mutation into the FCMD gene in Japanese patients with Fukuyama congenital muscular dystrophy. Am J Med Genet A. 2004;127A:54-7. PMID: 15103718.
5. Zhang H, Nanba E, Yamamoto T, Ninomiya H, Ohno K, Mizuguchi M, et al. Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex. J Hum Genet. 1999;44:391-6. PMID: 10570911.
6. Wu J, Jiang R. Prediction of deleterious nonsynonymous single-nucleotide polymorphism for human diseases. SciencetificWorldJournal. 2013;2013:675851. PMID: 23431257.
7. Fujimoto S, Manabe Y, Fuji D, Kozai Y, Matsuzoku K, Takahashi Y, et al. A novel mutation of the GAA gene in a patient with adult-onset Pompe disease lacking a disease-specific pathology. Intern Med. 2013;52:2461-4. PMID: 24190153.
8. Chiba Y, Komori H, Takei S, Hasegawa-Ishii S, Kawamura N, Adachi K, et al. Niemann-Pick disease type C1 predominantly involving the frontotemporal region, with cortical and brainstem Lewy bodies: an autopsy case. Neuropathology. 2013 May 27. [Epub ahead of print]. PMID: 23711246.
9. Sekijima Y, Nakamura K, Kishida D, Narita A, Adachi K, Ohno K, et al. Clinical and serial MRI findings of a sialidosis type I patient with a novel missense mutation in the NEU1 gene. Intern Med. 2013;52:119-24. PMID: 23291686.
10. Xiong H, Higaki K, Wei CI, Bao XH, Zhang YH, Fu N, et al. Genotype/phenotype of 6 Chinese cases with Niemann-Pick disease type C1 gene. Intern Med. 2012;498:332-5. PMID: 22326530.
11. Muraoka T, Murao K, Imachi H, Kikuchi F, Yoshimoto T, Iwama H, et al. Novel mutations in the gene encoding α-1,4-glucosidase in a patient with late-onset glycogen storage disease type II (Pompe disease) with impaired intelligence. Intern Med. 2011;50:2987-91. PMID: 22189990.
12. Higaki K, Li L, Bahrudin U, Okuzawa S, Takamuram A, Yamamoto K, et al. Chemical chaperone therapy; chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency. Hum Mutat. 2011;32:843-52. PMID: 21520340.
13. Watanabe T, Yoshida Y, Adachi K, Nanba E, Yamamoto O. Multiple subcutaneous hard nodules. Clin Exp Dermatol. 2010;35:681-2. PMID: 20642802.
14. Ishii K, Hosaka A, Adachi K, Nanba E, Tamaoka A. A Japanese case of fragile-X-associated tremor/ataxia syndrome (FXTAS). Intern Med. 2010;49:1205-8. PMID: 20558944.
15. Kinoshita T, Hanaki K, Nagaishi J, Kawashima Y, Adachi K, Nanba E, et al. Variation analysis of beta3-adrenergic receptor and melanocortin-4 receptor genes in childhood obesity. Pediatr Int. 2007;49:133-7. PMID: 17445027.
16. Maeda N, Horie Y, Sasaki Y, Adachi K, Nanba E, Nishida K, et al. Three novel mutations in the protoporphyrinogen oxidase gene in Japanese patients with variegate porphyria. Clin Biochem. 2000;33:495-500. PMID: 11074242.
17. Maeda N, Horie Y, Adachi K, Nanba E, Kawasaki H, Daimon M, et al. Two deletion mutations in the hydroxymethylbilane synthase gene in two unrelated Japanese patients with acute intermittent porphyria. J Hum Genet. 2000;45:263-8. PMID: 10944860.
18. Kato K, Shimomura T, Murakami F, Ikawa S, Kanaoka Y, Ohi S, et al. Allele frequency of human endothelial nitric oxide synthase gene polymorphism in abdominal aortic aneurysm. Intern Med. 2000;39:537-9. PMID: 10888208.
19. Nanba E, Ito T, Kadowaki K, Makio A, Nakagawa M,
Yamamoto T, et al. Prenatal diagnosis of congenital myotonic dystrophy in two Japanese families: direct mutation analysis by a non-radioisotope PCR method and haplotype analysis with flanking DNA markers. Brain Dev. 1996;18:122-6. PMID: 8733903.

20 Nanba E, Kohno Y, Matsuda A, Yano M, Sato C, Hashimoto K, et al. Non-radioactive DNA diagnosis for the fragile X syndrome in mentally retarded Japanese males. Brain Dev. 1995;17:317-21, discussion 323-4. PMID: 8579216.

21 Yamamoto T, Nanba E, Ninomiya H, Higaki K, Taniguchi M, Zhang H, et al. NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. Hum Genet. 1999;105:10-6. PMID: 10480349.

22 Nishimoto J, Nanba E, Inui K, Okada S, Suzuki K. GM1-gangliosidosis (genetic beta-galactosidase deficiency): identification of four mutations in different clinical phenotypes among Japanese patients. Am J Hum Genet. 1991;49:566-74. PMID: 1909089.

23 Tsuji S. Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Hum Mol Genet. 2010;19(R1):R65-70. PMID: 20413655.

24 Najmabadi H, Hu H, Garshaseh M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature. 2011;478:57-63. PMID: 21937992.

25 Koshimizu E, Miyatake S, Okamoto N, Nakashima M, Tsursaki Y, Miyake N, et al. Performance comparison of bench-top next generation sequencers using microdroplet PCR-based enrichment for targeted sequencing in patients with autism spectrum disorder. PLoS One. 2013;8:e74167. PMID: 2406614.

26 Tsuji S, Matsubara Y, Okuyama T, Goto Y, Saito K, Miyachi H, et al. [General working report for a study on the effective enforcement system for the diagnosis by genetic techniques: from the second quarter of 2010 to the first quarter of 2012. Research on measures for intractable diseases; Japan Health and Labour Sciences Research Grant]. MHLW Grant System [Internet]. Tokyo: National Institute of Public Health (Japan); 1997 -. [cited 2013 Jun 10]. 118 p. Available from: http://mhlw-grants.nih.go.jp/niph/NIDD00;201231014B. Japanese.